Cargando…
A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping...
Autor principal: | Langley, Paul C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401370/ https://www.ncbi.nlm.nih.gov/pubmed/36033123 http://dx.doi.org/10.24926/iip.v12i4.4390 |
Ejemplares similares
-
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023) -
Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023) -
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2022) -
Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018) -
Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)